$0.82
3.40%
Nasdaq, Sep 25, 12:28 pm EDT. Market open.
ISIN
US87978U1088
Symbol
TPST

Tempest Therapeutics Inc Stock price

$0.85
-0.25 22.73% 1M
-0.90 51.43% 6M
-2.02 70.38% YTD
-8.35 90.76% 1Y
-4.05 82.67% 3Y
-188.30 99.55% 5Y
-23,223.65 100.00% 10Y
-21,936.65 100.00% 20Y
Nasdaq, Closing price Thu, Sep 24 2026
-0.07 7.81%
ISIN
US87978U1088
Symbol
TPST
Industry

Is Tempest Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$13.6m
Enterprise Value
$12.8m
Net debt
positive
Cash
$780.0k
Shares outstanding
16.0m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
39.4%
Return on Equity
-393.9%
ROCE
-356.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-18.2m
EBIT
$-18.5m
Net Income
$-40.5m
Free Cash Flow
$-20.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
57.7%
EBIT
57.4%
Net Income
6.1%
Free Cash Flow
43.7%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-2.7
FCF per Share
$-1.3
Short interest
4.8%
Employees
4
Rev per Employee
$0.0

Tempest Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Tempest Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Tempest Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Tempest Therapeutics Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
14% 14%
-
- Research and Development Expense 3.04 3.04
90% 90%
-
-18 -18
58% 58%
-
- Depreciation and Amortization 0.25 0.25
11% 11%
-
EBIT (Operating Income) EBIT -18 -18
57% 57%
-
Net Profit -40 -40
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tempest Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tempest Therapeutics Inc Stock News

Neutral
GlobeNewsWire
●
2 days ago
BRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that Nancy Freda-Smith has been appointed to its board of directors and will serve as Chair of the Audit Committee.
Neutral
GlobeNewsWire
●
10 days ago
-Transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year
Neutral
GlobeNewsWire
●
14 days ago
$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants $2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants
More Tempest Therapeutics Inc News

Company Profile

Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. It develops small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. The company is headquartered in South San Francisco, CA.

Head office United States
CEO Dr. Angel
Employees 4
Founded 2011
Website www.tempesttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today